- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The development of an easy to use, low cost method of detecting dengue virus in mosquitoes based on gold nanoparticles is reported in BioMed Central's open access journal Virology Journal. The assay is able to detect lower levels of the virus than current tests, and is easy to transport and use in remote regions.
Half the world's population is at risk of Dengue virus infection - it infects 50-100 million people per year, approximately half a million of these require hospitalization and 2.5% (most of which are children) will die. It is one of the most dangerous viruses in the world with no vaccine, and it does not respond to antiviral therapy. The main method of controlling infection remains destruction of the standing water where the mosquitoes, which transmit the virus to people, breed.
It is consequently vitally important to have a way of determining if mosquitoes are carrying Dengue virus, which can be used on site and that does not require specialist equipment.
Researchers from the University of Notre Dame, USA, used a DNAzyme linked to gold nanoparticles which recognises a short sequence of the viral RNA genome common to all four types of Dengue. Once bound, adding magnesium and heating to 37C causes the DNAZyme to cut the RNA leaving the gold nanoparticles free to clump together. This aggregation can be easily seen as a red to clear/colourless colour change.
The components of this test are stable at temperatures above 30C which means that they are easy to store and transport and the assay is able to detect as little as 10 viruses in each sample containing 10-20 mosquitoes.
The ultimate goal is to detect virus infection in just a single infected mosquito or cell. Dr James Carter, the lead author of this study explained, "Full development of our novel DDZ-AuNP detection method will provide a practical, rapid, and low cost alternative for the detection of DENV in mosquito cells and tissues, and possibly infected patient serum, in a matter of minutes with little to no specialized training required."
About BioMed Central Limited
BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
For more information, please click here
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: +44 (0) 20 3192 2370
Mob: +44 (0) 778 698 1967
Copyright © AlphaGalileoIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers